期刊
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
卷 50, 期 1, 页码 90-112出版社
TAYLOR & FRANCIS LTD
DOI: 10.3109/00365521.2014.968864
关键词
Crohn's disease; inflammatory bowel disease; ulcerative colitis
资金
- AbbVie
- Boerrhinger
- Cosmo
- Ferring
- Genentech
- GSK
- Novo Nordisk
- NPS
- Pfizer
- Takeda
Most patients with inflammatory bowel diseases (IBD) are offered conventional medical therapy, because emerging therapies for IBD are regulated by health-care jurisdiction and often limited to academic centres. This review distils current evidence to provide a pragmatic approach to conventional IBD therapy, including aminosalicylates, corticosteroids, thiopurines, methotrexate, calcineurin inhibitors, infliximab and adalimumab. It addresses drug efficacy, safety and salient practice points for optimal and appropriate practice.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据